BIOMARKER:

ROS1 positive

Entrez ID:

Related biomarkers:

‹

›

ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	TPX-0005 Sensitive: B - Late Trials Turning Point Therapeutics Press Release - 1 week (NewB)	TPX-0005 Sensitive: B - Late Trials Turning Point Therapeutics Press Release - 1 week - (New B)
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A1 - Approval	crizotinib Sensitive: A1 - Approval
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	entrectinib Sensitive: A1 - Approval	entrectinib Sensitive: A1 - Approval
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	lorlatinib Sensitive: A2 - Guideline	lorlatinib Sensitive: A2 - Guideline
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ceritinib Sensitive: A2 - Guideline	ceritinib Sensitive: A2 - Guideline
ROS1 positive ROS1 positive	Lung Cancer Lung Cancer	ROS1 positive ROS1 positive	Lung Cancer Lung Cancer	lorlatinib Sensitive: C2 – Inclusion Criteria	lorlatinib Sensitive: C2 – Inclusion Criteria
ROS1 positive ROS1 positive	Solid Tumor Solid Tumor	ROS1 positive ROS1 positive	Solid Tumor Solid Tumor	TQ-B3101 Sensitive: C2 – Inclusion Criteria	TQ-B3101 Sensitive: C2 – Inclusion Criteria
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	brigatinib Sensitive: C2 – Inclusion Criteria	brigatinib Sensitive: C2 – Inclusion Criteria
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	TQ-B3101 Sensitive: C2 – Inclusion Criteria	TQ-B3101 Sensitive: C2 – Inclusion Criteria
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	TQ-B3139 Sensitive: C3 – Early Trials	TQ-B3139 Sensitive: C3 – Early Trials
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	AB-106 Sensitive: C3 – Early Trials	AB-106 Sensitive: C3 – Early Trials
ROS1 positive ROS1 positive	Solid Tumor Solid Tumor	ROS1 positive ROS1 positive	Solid Tumor Solid Tumor	TPX-0005 Sensitive: C3 – Early Trials	TPX-0005 Sensitive: C3 – Early Trials
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ensartinib Sensitive: C3 – Early Trials	ensartinib Sensitive: C3 – Early Trials